IN2014CN04009A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04009A
IN2014CN04009A IN4009CHN2014A IN2014CN04009A IN 2014CN04009 A IN2014CN04009 A IN 2014CN04009A IN 4009CHN2014 A IN4009CHN2014 A IN 4009CHN2014A IN 2014CN04009 A IN2014CN04009 A IN 2014CN04009A
Authority
IN
India
Prior art keywords
apoaequorin
neurons
subject
injury due
neuronal injury
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Y Underwood
James R Moyer
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of IN2014CN04009A publication Critical patent/IN2014CN04009A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN4009CHN2014 2011-11-15 2012-11-15 IN2014CN04009A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559816P 2011-11-15 2011-11-15
PCT/US2012/065291 WO2013074798A1 (fr) 2011-11-15 2012-11-15 Apoaéquorine pour réduire une lésion neuronale due à une ischémie

Publications (1)

Publication Number Publication Date
IN2014CN04009A true IN2014CN04009A (fr) 2015-10-23

Family

ID=47295186

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4009CHN2014 IN2014CN04009A (fr) 2011-11-15 2012-11-15

Country Status (24)

Country Link
US (1) US20140294874A1 (fr)
EP (1) EP2780027B1 (fr)
JP (1) JP6181061B2 (fr)
KR (1) KR102009932B1 (fr)
CN (1) CN104244966B (fr)
AU (1) AU2012340446B2 (fr)
BR (1) BR112014011630A2 (fr)
CA (1) CA2855719C (fr)
CY (1) CY1119300T1 (fr)
DK (1) DK2780027T3 (fr)
ES (1) ES2643392T3 (fr)
HK (1) HK1202417A1 (fr)
HR (1) HRP20171532T1 (fr)
HU (1) HUE035017T2 (fr)
IL (1) IL232494B (fr)
IN (1) IN2014CN04009A (fr)
LT (1) LT2780027T (fr)
MX (1) MX350259B (fr)
PL (1) PL2780027T3 (fr)
PT (1) PT2780027T (fr)
SG (1) SG11201402364WA (fr)
SI (1) SI2780027T1 (fr)
WO (1) WO2013074798A1 (fr)
ZA (1) ZA201403577B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
KR20180001229A (ko) 2016-06-27 2018-01-04 삼성에스디아이 주식회사 이차 전지의 제조 방법 및 이를 이용한 이차 전지
JP2019532936A (ja) * 2016-09-23 2019-11-14 クインシー バイオサイエンス,リミティド ライアビリティ カンパニー アポエクオリンおよびビタミンd含有組成物およびそれらの使用方法
RU2642961C1 (ru) * 2017-02-21 2018-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии головного мозга

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
CA2717322C (fr) * 2008-03-11 2017-07-11 Quincy Bioscience, Llc Compositions contenant de l'apoaequorine et leurs procedes d'utilisation
WO2010017500A2 (fr) * 2008-08-08 2010-02-11 Immunomedics, Inc. Anticorps anti-cancer pancréatique
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Also Published As

Publication number Publication date
IL232494B (en) 2019-03-31
LT2780027T (lt) 2017-10-25
CA2855719C (fr) 2021-10-26
CA2855719A1 (fr) 2013-05-23
AU2012340446B2 (en) 2017-08-31
WO2013074798A1 (fr) 2013-05-23
EP2780027B1 (fr) 2017-07-19
HK1202417A1 (en) 2015-10-02
JP6181061B2 (ja) 2017-08-16
NZ624736A (en) 2016-05-27
MX350259B (es) 2017-08-31
DK2780027T3 (en) 2017-09-25
KR102009932B1 (ko) 2019-08-12
HUE035017T2 (en) 2018-03-28
CN104244966A (zh) 2014-12-24
SI2780027T1 (sl) 2017-11-30
JP2014533692A (ja) 2014-12-15
CN104244966B (zh) 2019-01-11
BR112014011630A2 (pt) 2017-06-27
AU2012340446A1 (en) 2014-05-29
SG11201402364WA (en) 2014-09-26
ES2643392T3 (es) 2017-11-22
IL232494A0 (en) 2014-06-30
KR20140097369A (ko) 2014-08-06
CY1119300T1 (el) 2018-02-14
US20140294874A1 (en) 2014-10-02
EP2780027A1 (fr) 2014-09-24
PL2780027T3 (pl) 2017-11-30
MX2014005798A (es) 2014-05-30
HRP20171532T1 (hr) 2017-11-17
ZA201403577B (en) 2015-07-29
PT2780027T (pt) 2017-10-04

Similar Documents

Publication Publication Date Title
MX2022009538A (es) Nanoportadores sinteticos tolerogenicos y macromoleculas terapeuticas para efectos farmacodinamicos reducidos o intensificados.
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
IN2014DN09434A (fr)
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
MY166014A (en) Combination therapy methods for treating proliferative diseases
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX2019009437A (es) Tratamiento de mielosupresion.
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
NZ631144A (en) Compositions and methods for transmucosal absorption
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX348708B (es) Métodos para mejorar el desarrollo del cerebro y la función cognoscitiva al usar beta-hidroxi-beta-metilbutirato.
IN2015DN03854A (fr)
MX336347B (es) Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.
IN2014MN02056A (fr)
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
WO2013173827A3 (fr) Procédés et compositions pour inhiber des maladies du système nerveux central
IN2014CN04009A (fr)
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
MX362905B (es) Tratamiento de combinacion.
WO2014170820A3 (fr) Combinaison pharmaceutique permettant de traiter la tuberculose
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".